Table 2.
Univariate analysis of CRRT group and non-CRRT group
| Variable | CRRT (n = 142) | non-CRRT (n = 45) | P |
|---|---|---|---|
| General condition | |||
| Age (years), median (IQR) | 71 (61.5, 74.5) | 68 (62, 76) | 0.431 |
| The male, n (%) | 77 (54.22%) | 42 (93.33%) | 0.158 |
| BMI, mean (SD) | 24.56 (4.82) | 25.00 (4.26) | 0.760 |
| Temperature (℃), median (IQR) | 36.7 (36.4, 37.7) | 37.2 (36.5, 37.7) | 0.746 |
| Heart rate, mean (SD) | 108 (19) | 99 (24) | 0.151 |
| Breathing, median (IQR) | 19 (15, 22) | 20 (18, 21) | 0.744 |
| MAP (mmHg), mean (SD) | 83.24 (10.17) | 81.86 (8.68) | 0.648 |
| Baseline Scr (μmol/L), median (IQR) | 67.4 (52.6, 82.25) | 73.6 (50.8, 81.4) | 0.867 |
| Reason for ICU admission, n (%) | |||
| Respiratory failure | 64 (45.07%) | 22 (48.89%) | 0.654 |
| Circulatory failure | 43 (30.28%) | 12 (26.67%) | 0.643 |
| Neurological diseases | 20 (14.08%) | 6 (13.33%) | 0.899 |
| Trauma | 6 (4.23%) | 2 (4.44%) | 0.950 |
| Others | 9 (6.34%) | 3 (6.67%) | 0.938 |
| Previous medical history, n (%) | |||
| Hypertension | 66 (46.48%) | 22 (48.88%) | 0.778 |
| Diabetes | 28 (19.72%) | 9 (20.00%) | 0.967 |
| Ischemic heart disease | 21 (14.79%) | 8 (17.77%) | 0.629 |
| Cerebrovascular disease | 38 (26.76%) | 15 (33.33%) | 0.394 |
| Chronic liver disease | 3 (2.11%) | 1 (2.22%) | 1.000 |
| Malignancy | 60 (42.25%) | 17 (37.78%) | 0.595 |
| Laboratory examination | |||
| WBC (109/L), mean (SD) | 17.87 (10.53) | 17.63 (12.73) | 0.945 |
| PLT (109/L), median (IQR) | 130 (84.25, 229.75) | 247.5 (141.25, 367) | 0.040 |
| PCT (ng/ml), median (IQR) | 7.42 (2.83, 20.81) | 2.98 (0.97, 8.69) | 0.045 |
| Scr (μmol/L), median (IQR) | 267.35 (196.8, 358.52) | 100.55 (64.87, 165.2) | 0.000 |
| BUN (mmol/L), median (IQR) | 18.36 (11.57, 29) | 9.2 (6.72, 19.06) | 0.009 |
| Total bilirubin (μmol/L), median (IQR) | 19.2 (9.1, 46.5) | 16.1 (9.75, 34.97) | 0.635 |
| Lactate (mmol/L), median (IQR) | 1.95 (1.32, 5.47) | 1.75 (1.27, 2.22) | 0.127 |
| Plasma NGAL (ng/ml), median (IQR) | 297.13 (174.79, 485.57) | 131.45 (87.36, 200.3) | 0.000 |
| pH, mean (SD) | 7.32 (0.11) | 7.39 (0.06) | 0.028 |
| Potassium concentration (mmol/L), median (IQR) | 4.46 (4.13, 5.32) | 4.3 (3.63, 4.54) | 0.074 |
| Bicarbonate (mmol/L), median (IQR) | 19.1 (14, 21.65) | 20.8 (19.8, 24.2) | 0.088 |
| Stage of AKI, n (%) | |||
| Stage 1, n (%) | 16 (11.27%) | 33 (73.33%) | 0.000 |
| Stage 2, n (%) | 33 (23.24%) | 3 (6.67%) | 0.014 |
| Stage 3, n (%) | 93 (65.49%) | 9 (20.00%) | 0.000 |
| Others | |||
| FST 2 h urine output (ml), median (IQR) | 35 (5, 143.75) | 400 (210, 890) | 0.000 |
| RRI, mean (SD) | 0.68 (0.08) | 0.63 (0.08) | 0.072 |
| CVP (mmHg), median (IQR) | 9 (8, 11) | 9 (8, 11) | 0.908 |
| Mechanical ventilation, n (%) | 98 (69.01%) | 28 (62.22%) | 0.397 |
| Sepsis, n (%) | 84 (59.15%) | 23 (51.11%) | 0.342 |
| SOFA score, mean (SD) | 10.13 (3.18) | 5.86 (2.72) | 0.000 |
| APACHE II score, median (IQR) | 22.5 (16, 29.5) | 16 (15, 18) | 0.006 |
BMI, body mass index; WBC, white blood cell; PLT, platelet; PCT, procalcitonin; Scr, serum creatinine; BUN, blood urea nitrogen; NGAL, neutrophil gelatinase-associated lipocalin; AKI, acute kidney injury; RRI, renal resistance index; CRRT, continuous renal replacement therapy; SOFA, Sequential Organ Failure Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II